Journal
TRENDS IN IMMUNOLOGY
Volume 40, Issue 4, Pages 328-344Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2019.02.004
Keywords
-
Categories
Funding
- Australian National Health and Medical Research Council (NHMRC) program [633004]
- Cancer Council New South Wales (CCNSW) [RG 18-05]
- Centenary Institute
- Melanoma Institute Australia
- New Zealand Institute for Cancer Research Trust
- Health Research Council of New Zealand
- Marsden Fund
- Cancer Research Trust NZ
- Dunedin School of Medicine Bequest, a University of Otago Research Grant
- Royal Society of New Zealand
Ask authors/readers for more resources
Methylation of DNA at CpG sites is the most common and stable of epigenetic changes in cancer. Hypermethylation acts to limit immune checkpoint blockade immunotherapy by inhibiting endogenous interferon responses needed for recognition of cancer cells. By contrast, global hypomethylation results in the expression of programmed death ligand 1 (PD-L1) and inhibitory cytokines, accompanied by epithelial-mesenchymal changes that can contribute to immunosuppression. The drivers of these contrasting methylation states are not well understood. DNA methylation also plays a key role in cytotoxic T cell 'exhaustion' associated with tumor progression. We present an updated exploratory analysis of how DNA methylation may define patient subgroups and can be targeted to develop tailored treatment combinations to help improve patient outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available